Dr. Berkley A. Lynch has worked in neuroscience drug discovery for more than 15 years, focusing most recently on diseases of neurodegeneration. He holds a PhD in biochemistry from The Rockefeller University in New York and has expertise in the full range of pre-clinical drug development activities, including biochemistry, cell and molecular biology, and in vitro and in vivo pharmacology. In his career, he has worked at ARIAD Pharmaceuticals, UCB Inc., Link Medicine and Dotmatics Inc. He has consulted for multiple biotechnology companies and now serves as senior director of CNS research at Rodin Therapeutics. Dr. Lynch has lead research identifying targets and developing assays around Parkinson’s and other neurodegenerative diseases and epilepsy, and has supervised testing of possible therapeutics in models of Parkinson’s and other diseases.